Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients

Matteo Nicola Dario Di Minno, Anna Russolillo, Alessandro Di Minno, Marina Camera, Alessandro Parolari, Elena Tremoli

Research output: Contribution to journalArticle

Abstract

Introduction: The usefulness of anticoagulation in patients with atrial fibrillation (AF) is well known. However, the inherent limitations of vitamin K antagonists (VKAs) have made the development of new oral anticoagulants necessary. Drugs directed against thrombin or the factor Xa are currently available. Areas covered: These molecules, being administered at fixed doses and not requiring laboratory monitoring, overcome one crucial problem associated with the use of VKAs. However, data about the bleeding risk related to the use of these molecules should be further analyzed. Expert opinion: The efficacy of direct anticoagulants (DACs) in AF-related stroke prevention has been considered the primary outcome in all Phase III published trials. On the other hand, the reduction of the bleeding risk is an important goal achieved by the DACs as compared with VKAs. Besides data deriving from randomized trials, when talking about new drugs, the need of evidences from the 'everyday clinical practice' are often requested. The aim of this literature revision is to report and analyze data from specific subgroups about which little is known. In particular, information about the use of DACs in oncologic patients, in patients receiving concomitant antiplatelet drugs and in the perioperative period is currently lacking. The parallel evaluation of all these data may lead to the identification of clinical and demographical criteria to choose when to switch to DACs.

Original languageEnglish
Pages (from-to)9-23
Number of pages15
JournalExpert Opinion on Emerging Drugs
Volume18
Issue number1
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Vitamin K
Anticoagulants
Atrial Fibrillation
Hemorrhage
Perioperative Period
Factor Xa
Platelet Aggregation Inhibitors
Expert Testimony
Risk Reduction Behavior
Thrombin
Pharmaceutical Preparations
Stroke

Keywords

  • Atrial fibrillation
  • New anticoagulant drugs
  • Stroke prevention

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients. / Di Minno, Matteo Nicola Dario; Russolillo, Anna; Di Minno, Alessandro; Camera, Marina; Parolari, Alessandro; Tremoli, Elena.

In: Expert Opinion on Emerging Drugs, Vol. 18, No. 1, 03.2013, p. 9-23.

Research output: Contribution to journalArticle

@article{9a4eaf9f01254bd5958029d81eeca886,
title = "Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients",
abstract = "Introduction: The usefulness of anticoagulation in patients with atrial fibrillation (AF) is well known. However, the inherent limitations of vitamin K antagonists (VKAs) have made the development of new oral anticoagulants necessary. Drugs directed against thrombin or the factor Xa are currently available. Areas covered: These molecules, being administered at fixed doses and not requiring laboratory monitoring, overcome one crucial problem associated with the use of VKAs. However, data about the bleeding risk related to the use of these molecules should be further analyzed. Expert opinion: The efficacy of direct anticoagulants (DACs) in AF-related stroke prevention has been considered the primary outcome in all Phase III published trials. On the other hand, the reduction of the bleeding risk is an important goal achieved by the DACs as compared with VKAs. Besides data deriving from randomized trials, when talking about new drugs, the need of evidences from the 'everyday clinical practice' are often requested. The aim of this literature revision is to report and analyze data from specific subgroups about which little is known. In particular, information about the use of DACs in oncologic patients, in patients receiving concomitant antiplatelet drugs and in the perioperative period is currently lacking. The parallel evaluation of all these data may lead to the identification of clinical and demographical criteria to choose when to switch to DACs.",
keywords = "Atrial fibrillation, New anticoagulant drugs, Stroke prevention",
author = "{Di Minno}, {Matteo Nicola Dario} and Anna Russolillo and {Di Minno}, Alessandro and Marina Camera and Alessandro Parolari and Elena Tremoli",
year = "2013",
month = "3",
doi = "10.1517/14728214.2013.777427",
language = "English",
volume = "18",
pages = "9--23",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients

AU - Di Minno, Matteo Nicola Dario

AU - Russolillo, Anna

AU - Di Minno, Alessandro

AU - Camera, Marina

AU - Parolari, Alessandro

AU - Tremoli, Elena

PY - 2013/3

Y1 - 2013/3

N2 - Introduction: The usefulness of anticoagulation in patients with atrial fibrillation (AF) is well known. However, the inherent limitations of vitamin K antagonists (VKAs) have made the development of new oral anticoagulants necessary. Drugs directed against thrombin or the factor Xa are currently available. Areas covered: These molecules, being administered at fixed doses and not requiring laboratory monitoring, overcome one crucial problem associated with the use of VKAs. However, data about the bleeding risk related to the use of these molecules should be further analyzed. Expert opinion: The efficacy of direct anticoagulants (DACs) in AF-related stroke prevention has been considered the primary outcome in all Phase III published trials. On the other hand, the reduction of the bleeding risk is an important goal achieved by the DACs as compared with VKAs. Besides data deriving from randomized trials, when talking about new drugs, the need of evidences from the 'everyday clinical practice' are often requested. The aim of this literature revision is to report and analyze data from specific subgroups about which little is known. In particular, information about the use of DACs in oncologic patients, in patients receiving concomitant antiplatelet drugs and in the perioperative period is currently lacking. The parallel evaluation of all these data may lead to the identification of clinical and demographical criteria to choose when to switch to DACs.

AB - Introduction: The usefulness of anticoagulation in patients with atrial fibrillation (AF) is well known. However, the inherent limitations of vitamin K antagonists (VKAs) have made the development of new oral anticoagulants necessary. Drugs directed against thrombin or the factor Xa are currently available. Areas covered: These molecules, being administered at fixed doses and not requiring laboratory monitoring, overcome one crucial problem associated with the use of VKAs. However, data about the bleeding risk related to the use of these molecules should be further analyzed. Expert opinion: The efficacy of direct anticoagulants (DACs) in AF-related stroke prevention has been considered the primary outcome in all Phase III published trials. On the other hand, the reduction of the bleeding risk is an important goal achieved by the DACs as compared with VKAs. Besides data deriving from randomized trials, when talking about new drugs, the need of evidences from the 'everyday clinical practice' are often requested. The aim of this literature revision is to report and analyze data from specific subgroups about which little is known. In particular, information about the use of DACs in oncologic patients, in patients receiving concomitant antiplatelet drugs and in the perioperative period is currently lacking. The parallel evaluation of all these data may lead to the identification of clinical and demographical criteria to choose when to switch to DACs.

KW - Atrial fibrillation

KW - New anticoagulant drugs

KW - Stroke prevention

UR - http://www.scopus.com/inward/record.url?scp=84874637323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874637323&partnerID=8YFLogxK

U2 - 10.1517/14728214.2013.777427

DO - 10.1517/14728214.2013.777427

M3 - Article

C2 - 23448155

AN - SCOPUS:84874637323

VL - 18

SP - 9

EP - 23

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 1

ER -